This umbrella review evaluates blood-based biomarkers’ diagnostic and prognostic performance in ovarian cancer, implying a need for improved detection methods.
Introduction: Ovarian cancer is a leading cause of gynaecological cancer mortality. Ca125, the most widely used serum biomarker, has limited sensitivity for early-stage and type I tumours, prompting evaluation of additional blood-based markers. This umbrella review assesses the diagnostic and prognostic performance of serum and blood biomarkers in ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: